RxDoctor Payments DataLook up a doctor →

David Krueger, MD

Physical Medicine & Rehabilitation · Naples, FLNPI 1730294620

Payments from drug & device makers

$9,786in general payments, 2019–2025

Across 436 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • AstraZeneca$904
  • AbbVie$509
  • Amgen$466
  • Lilly USA, LLC$406
  • Teva Pharmaceuticals USA, Inc.$388
  • plus $6K from 52 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.40$1,149
AstraZeneca(2 entities)28$904
AbbVie31$509
Amgen(2 entities)23$466
Lilly USA, LLC26$406
Teva Pharmaceuticals USA, Inc.19$388
GE HealthCare23$382
Eisai Inc.14$351
Abbott3$338
Neurocrine Biosciences, Inc.12$329
Acadia Pharmaceuticals Inc15$292
Neurelis, Inc.17$290
Amneal Pharmaceuticals LLC15$271
Merz Pharmaceuticals, LLC10$256
Novartis20$237
Acorda Therapeutics, Inc8$199
Lundbeck LLC8$193
Avanir Pharmaceuticals, Inc.11$192
Biogen4$183
Johnson & Johnson(2 entities)12$180
Medtronic(2 entities)3$163
Sanofi6$146
Merz North America, Inc.6$133
Biodelivery Sciences International, Inc.1$125
Scilex Pharmaceuticals Inc.5$118
Pfizer6$118
Kyowa Kirin, Inc.6$115
Biohaven Pharmaceutical Holding Company Ltd.5$106
Bristol Myers Squibb5$104
Argenx US, Inc.5$102
Biohaven Pharmaceuticals, Inc.4$88
MDD US Operations, LLC4$81
E.r. Squibb & Sons, L.L.C.4$73
Sumitomo Pharma America, Inc.3$72
SK Life Science, Inc.2$68
Adamas Pharmaceuticals, Inc.3$47
Tanabe Pharma America, Inc.3$47
Azurity Pharmaceuticals, Inc.2$44
Vanda Pharmaceuticals Inc.2$44
Xeris Pharmaceuticals, Inc.2$43
Takeda Pharmaceuticals U.S.A., Inc.1$35
Averitas Pharma Inc.1$34
Almatica Pharma LLC2$34
Sunovion Pharmaceuticals Inc.2$32
Mallinckrodt Hospital Products Inc.1$32
Novocure Inc.1$29
Octapharma USA, Inc.1$26
Collegium Pharmaceutical, Inc.1$25
Boston Scientific1$23
Catalyst Pharmaceuticals, Inc.1$21
Aprecia Pharmaceuticals, LLC1$21
Banner Life Sciences, LLC1$20
TG Therapeutics, Inc.1$19
Nevro Corp.1$19
Otsuka America Pharmaceutical, Inc.1$17
Livanova USA, Inc.1$17
Upsher-smith Laboratories LLC1$16
Cala Health, Inc.1$16

How this compares

$9,786 in reported general payments places this provider in the 95th percentile of 618 physical medicine & rehabilitation providers in Florida.

See all physical medicine & rehabilitation providers in Florida

Medicare billing

Part B allowed, 2024
$477,629
Medicare patients
840
Services billed
7,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other physical medicine & rehabilitation in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →